Vanton Research Laboratory, LLC

vantonlab.com

Vanton Resesarch Laboratory. LLC is a rapid growing pharmaceutical CRO and a specialty pharma company with California HHS granted GMP facility and DEA granted controlled substance license, we specialize in developing novel platform technologies and niche drug delivery systems for various dosage forms – oral controlled release and sustained release tablets, rapid disintegration tablets, transdermal patches, injectable solutions, suspensions, emulsions, microparticles, and liposome formulations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

news image

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More

Views and Analysis

EVEREST MEDICINES ANNOUNCES PARTNER CALLIDITAS THERAPEUTICS RECEIVES FDA PRIORITY REVIEW FOR FULL APPROVAL OF NEFECON®

PRNewswire | August 21, 2023

news image

Everest Medicines announced that U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date is Dec. 20, 2023. "We congratulate our partner Calliditas for being granted priority review by the FDA for full approval and taking a step closer to offering this first-in-disease thera...

Read More

Business Insights

NOVAVAX SUBMITS APPLICATION TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION FOR NOVAVAX COVID-19 VACCINE,

Novavax, Inc. | August 16, 2022

news image

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it submitted an application to the U.S. Food and Drug Administration for Emergency Use Authorization of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a homologous and heterologous booster in adults aged 18 a...

Read More

Business Insights

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

news image

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More
news image

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More
news image

Views and Analysis

EVEREST MEDICINES ANNOUNCES PARTNER CALLIDITAS THERAPEUTICS RECEIVES FDA PRIORITY REVIEW FOR FULL APPROVAL OF NEFECON®

PRNewswire | August 21, 2023

Everest Medicines announced that U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date is Dec. 20, 2023. "We congratulate our partner Calliditas for being granted priority review by the FDA for full approval and taking a step closer to offering this first-in-disease thera...

Read More
news image

Business Insights

NOVAVAX SUBMITS APPLICATION TO THE U.S. FDA FOR EMERGENCY USE AUTHORIZATION FOR NOVAVAX COVID-19 VACCINE,

Novavax, Inc. | August 16, 2022

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it submitted an application to the U.S. Food and Drug Administration for Emergency Use Authorization of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a homologous and heterologous booster in adults aged 18 a...

Read More
news image

Business Insights

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us